These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15069189)

  • 1. Development of an efficient, scalable, aldolase-catalyzed process for enantioselective synthesis of statin intermediates.
    Greenberg WA; Varvak A; Hanson SR; Wong K; Huang H; Chen P; Burk MJ
    Proc Natl Acad Sci U S A; 2004 Apr; 101(16):5788-93. PubMed ID: 15069189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.
    Andrushko N; Andrushko V; Tararov V; Korostylev A; König G; Börner A
    Chirality; 2010 May; 22(5):534-41. PubMed ID: 19899159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streamlined catalytic asymmetric synthesis of atorvastatin.
    Kawato Y; Chaudhary S; Kumagai N; Shibasaki M
    Chemistry; 2013 Mar; 19(12):3802-6. PubMed ID: 23436316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactone pathway to statins utilizing the Wittig reaction. The synthesis of rosuvastatin.
    Casar Z; Steinbücher M; Kosmrlj J
    J Org Chem; 2010 Oct; 75(19):6681-4. PubMed ID: 20815370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly productive, whole-cell DERA chemoenzymatic process for production of key lactonized side-chain intermediates in statin synthesis.
    Ošlaj M; Cluzeau J; Orkić D; Kopitar G; Mrak P; Casar Z
    PLoS One; 2013; 8(5):e62250. PubMed ID: 23667462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
    Chitose T; Sugiyama S; Sakamoto K; Shimomura H; Yamashita T; Hokamaki J; Tsunoda R; Shiraishi S; Yamashita Y; Ogawa H
    Atherosclerosis; 2014 Nov; 237(1):251-8. PubMed ID: 25262434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New light on statin side effects. What recent research on the cholesterol drugs means to you.
    Heart Advis; 2005 Aug; 8(8):3. PubMed ID: 16193557
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):1013-22. PubMed ID: 25240453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW; Kang SJ; Ahn JM; Song HG; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2012 Jun; 109(12):1700-4. PubMed ID: 22440123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
    Satoh M; Tabuchi T; Itoh T; Nakamura M
    Clin Sci (Lond); 2014 Feb; 126(3):233-41. PubMed ID: 23944632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
    de Zeeuw D; Anzalone DA; Cain VA; Cressman MD; Heerspink HJ; Molitoris BA; Monyak JT; Parving HH; Remuzzi G; Sowers JR; Vidt DG
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):181-90. PubMed ID: 25660356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a novel tablet splitter.
    Shao J; Polli JE
    J Am Pharm Assoc (2003); 2007; 47(2):185-7. PubMed ID: 17510006
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
    Kurtoglu E; Balta S; Sincer I; Altas Y; Atas H; Yilmaz M; Korkmaz H; Erdem K; Akturk E; Demirkol S; Can C
    Angiology; 2014 Oct; 65(9):788-93. PubMed ID: 24163120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
    Folse H; Sternhufvud C; Andy Schuetz C; Rengarajan B; Gandhi S
    Clin Ther; 2014 Jan; 36(1):58-69. PubMed ID: 24417785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.